Barclays PLC Protagonist Therapeutics, Inc Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Barclays PLC holds 126,733 shares of PTGX stock, worth $4.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,733

Previous 126,995 0.21%

Holding current value

$4.91 Million

Previous $5.71 Million 14.4%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$38.51 - $48.43 $10,089 - $12,688	-262 Reduced 0.21%	126,733 $4.89 Million
Q3 2024 Nov 15, 2024	BUY	$33.72 - $47.33 $2.96 Million - $4.15 Million	87,755 Added 223.64%	126,995 $5.71 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $556,798 - $785,749	-22,579 Reduced 36.52%	39,240 $1.36 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $1.9 Million - $2.8 Million	-87,155 Reduced 58.5%	61,819 $1.79 Million
Q4 2023 Feb 15, 2024	SELL	$14.05 - $23.44 $391,475 - $653,108	-27,863 Reduced 15.76%	148,974 $3.42 Million
Q3 2023 Nov 07, 2023	SELL	$16.68 - $23.66 $276,921 - $392,803	-16,602 Reduced 8.58%	176,837 $2.95 Million
Q2 2023 Aug 03, 2023	SELL	$18.02 - $29.36 $7.03 Million - $11.5 Million	-390,298 Reduced 66.86%	193,439 $5.34 Million
Q1 2023 May 04, 2023	BUY	$10.78 - $25.38 $3.55 Million - $8.35 Million	328,850 Added 129.02%	583,737 $13.4 Million
Q4 2022 Feb 13, 2023	BUY	$7.36 - $11.17 $286,252 - $434,434	38,893 Added 18.01%	254,887 $2.78 Million
Q3 2022 Nov 03, 2022	BUY	$7.86 - $11.71 $1.51 Million - $2.25 Million	192,463 Added 817.91%	215,994 $1.82 Million
Q2 2022 Aug 12, 2022	SELL	$7.06 - $25.52 $146,643 - $530,075	-20,771 Reduced 46.89%	23,531 $186,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $1.78 Million - $2.75 Million	-76,295 Reduced 63.26%	44,302 $1.05 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $1.47 Million - $3.1 Million	83,600 Added 225.96%	120,597 $4.12 Million
Q3 2021 Nov 09, 2021	BUY	$12.95 - $49.69 $383,216 - $1.47 Million	29,592 Added 399.62%	36,997 $656,000
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $778,887 - $1.37 Million	-30,461 Reduced 80.44%	7,405 $333,000
Q1 2021 May 13, 2021	BUY	$19.02 - $31.15 $518,447 - $849,086	27,258 Added 256.96%	37,866 $981,000
Q4 2020 Feb 11, 2021	SELL	$18.49 - $25.13 $72,462 - $98,484	-3,919 Reduced 26.98%	10,608 $214,000
Q3 2020 Nov 12, 2020	BUY	$15.19 - $22.4 $29,407 - $43,366	1,936 Added 15.38%	14,527 $284,000
Q2 2020 Aug 12, 2020	BUY	$6.19 - $18.84 $41,460 - $126,190	6,698 Added 113.66%	12,591 $222,000
Q1 2020 May 13, 2020	SELL	$5.4 - $9.22 $67,829 - $115,812	-12,561 Reduced 68.07%	5,893 $42,000
Q4 2019 Feb 10, 2020	BUY	$4.69 - $13.45 $18,553 - $53,208	3,956 Added 27.29%	18,454 $130,000
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $98,588 - $173,499	-10,477 Reduced 41.95%	14,498 $174,000
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $355,554 - $513,138	-39,594 Reduced 61.32%	24,975 $302,000
Q1 2019 May 15, 2019	SELL	$6.5 - $13.77 $26,214 - $55,534	-4,033 Reduced 5.88%	64,569 $812,000
Q4 2018 Feb 14, 2019	BUY	$6.3 - $10.44 $432,192 - $716,204	68,602 New	68,602 $462,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $167,274 - $276,174	-24,527 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $75,773 - $115,115	12,650 Added 106.51%	24,527 $164,000
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $30,972 - $84,495	3,661 Added 44.56%	11,877 $102,000
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $115,760 - $166,400	8,000 Added 3703.7%	8,216 $171,000
Q3 2017 Nov 14, 2017	BUY	$10.61 - $17.98 $2,291 - $3,883	216	216 $4,000

Others Institutions Holding PTGX

# of Institutions

254

Shares Held

58.9M

Call Options Held

226K

Put Options Held

218K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.9B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account